Table 1

Characteristics of included clinical trials in meta-analysis

Study

Region

Study type

NA regimens (/day)

Sample size (n) (treatment vs. placebo)

Mean age (ys) (treatment vs. placebo)

Male(%) (treatment vs. placebo)

Mean ALT(U/L) (treatment vs. placebo)

Pre-existing cirrhosis(%) (treatment vs. placebo)

HBeAg (+) (%) (treatment vs. placebo)

Mean treatment duration (mon)

Follow up period (ys)


Papatheodoridis et al.[24]

Greece

Cohort

LAM 100 or 150 mg then add or switch to ADV

396 (201 vs. 195)

55.9 (52 ± 11) vs. (49 ± 14)

82.6 (83.1 vs. 82.1)

83.2 (98 vs. 68)

33.3 (31.8 vs. 34.9)

0

48

3.8

Matsumoto et al.[25]

Japan

Case-control

LAM 100 mg

754 (377 vs. 377)

41.5 (41.5 ± 12.0) vs. (41.4 ± 12.2)

72.8 (73.2 vs. 72.4)

171.6 (191.7 ± 234.8) vs. (151.5 ± 180.5)

17.5 (17.2 vs. 17.8)

54.8 (51.2 vs. 58.4)

18.9

2.7

Yuen et al.[26]

Hong Kong

Cohort

LAM 100 mg

266 (142 vs. 124)

33.7 (33.9 vs. 33.4)

73.7 (74.7 vs. 72.6)

61 (65 vs. 56.5)

0

100 (100 vs. 100)

89.9

8.2

Liaw et al.[23]

Taiwan

RCT

LAM 100 mg

651 (436 vs. 215)

43.3 (43 vs. 44)

85 (85 vs. 85)

69.3 (70 vs. 68)

61.3 (60 vs. 65)

58 (58 vs. 58)

32.4

2.7

Eun et al.[27]

Korea

RCT

LAM 100 mg then add or switch to ADV

222 (111 vs. 111)

M

M

M

100

M

M

4.4

Jong Ryul Eun et al.[28]

Korea

Cohort

LAM

1355 (768 vs. 587)

36.8 (39.2 vs. 33.6)

M

152.7 (161.3 vs. 141.4)

50.9 (67.3 vs. 25.2)

85.2 (80.1 vs. 91.8)

More than 48

4.4


M: Data missing in the studies; LAM: Lamivudine; ADV: Adefovir dipivoxil

Zhang et al. Virology Journal 2011 8:72   doi:10.1186/1743-422X-8-72

Open Data